MedTrace Logo

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

NCT05132777 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2021-11-24

No results posted yet for this study

Summary

This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Conditions

Interventions

DRUG

JMT101

JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Osimertinib Mesylate Tablets

Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    collaborator INDUSTRY

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Li Zhang · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-20
Primary Completion
2023-09-30
Completion
2024-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132777 on ClinicalTrials.gov